Recent News

• 06.09.2025 - Acurx Pharmaceuticals Announces Presentation of Results from Leiden University Medical Center Public-Private Partnership for Its DNA pol IIIC Inhibitors at the Federation of American Societies for Experimental Biology Scientific Conference
• 05.29.2025 - ARS - Annual Report to Security Holders
• 05.13.2025 - Acurx Pharmaceuticals, Inc. Reports First Quarter Results and Provides Business Update
• 04.30.2025 - Acurx Pharmaceuticals to Discuss First Quarter 2025 Financial Results on May 13, 2025 Conference Call and Provide Business Update
• 04.28.2025 - Acurx Pharmaceuticals to Present at the Alliance Global Partners (A.G.P) Healthcare Company Showcase
• 04.17.2025 - Indian Patent Office Grants Acurx Patent for DNA Polymerase IIIC Inhibitors

Recent Filings

• 05.29.2025 - 424B3 Prospectus [Rule 424(b)(3)]
• 05.29.2025 - DEF 14A Other definitive proxy statements
• 05.29.2025 - ARS Annual Report to Security Holders
• 05.29.2025 - EFFECT Notice of Effectiveness
• 05.29.2025 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
• 05.21.2025 - S-1 General form for registration of securities under the Securities Act of 1933
• 05.20.2025 - D Notice of Exempt Offering of Securities
• 05.19.2025 - PRE 14A Other preliminary proxy statements
• 05.13.2025 - 8-K Current report
• 05.13.2025 - EX-99.1 EX-99.1